Edison initiates coverage of Derma Sciences
NEW YORK, Sept. 20, 2013 /PRNewswire/ -- Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Derma Sciences (DSCI), a US medical device and pharmaceutical company developing and marketing products for advanced wound care.
Edison has published a comprehensive report examining the investment merits of Derma Sciences, focusing in particular on the growth prospects of its advance wound care unit and its lead wound healing product, DSC127, currently in two Phase III trials, STRIDE 1 and 2, which are expected to report top-line results in H115. Edison has valued Derma Sciences at $357.3m based on a risk-adjusted net present value model.
For the full report see: www.edisoninvestmentresearch.com/research/company/derma-sciences
The launch of coverage on Derma Sciences is part of a programme of research initiations on healthcare companies. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation without any specific stock recommendation.
All reports published by Edison are available to download free of charge from www.edisongroup.com.
About Edison Investment Research
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact:
Jason Zhang, Ph.D. Edison Investment Research +1 646 653 7026
About Derma Sciences
Derma Sciences is a specialty medical device/pharmaceutical company. It focuses on developing and commercialising traditional and novel advanced wound care products, including MEDIHONEY and TCC-EZ, among other brands, and DSC127, a novel pharmaceutical agent for wound healing. It is headquartered in Princeton, New Jersey, US.
SOURCE Edison Investment Research